Patients bearing tumours expressing high NCL mRNA levels, but also unexpectedly the ones expressing low NCL mRNA levels, had poorer overall and disease-free survivals than other breast cancer patients even when adjusted to two robust clinical factors, tumour size and lymph node invasion status. This evidence concerns the gene NUCLEOLIN and breast carcinoma.